Erratum: The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: A population-based from the Canadian multicentre osteoporosis study (CaMos) (American Journal of Gastroenterology (2012) 107 (1361-1369) DOI: 10.1038/ajg.2012.200);The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: A population-based from the canadian multicentre osteoporosis study (CaMos)

American Journal of Gastroenterology

Volumn 107, Issue 9, 2012, Pages 1361-1369

  Targownik, Laura E ^a   Leslie, William D ^a   Davison, K Shawn ^b   Goltzman, David ^c   Jamal, Sophie A ^d   Kreiger, Nancy ^d   Josse, Robert G ^d   Kaiser, Stephanie M ^e   Kovacs, Christopher S ^f   Prior, Jerilynn C ^g   Zhou, Wei ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

^f MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID; NITRATE; PROTON PUMP INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; BONE DENSITY; CANADA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EXPOSURE; DRUG USE; FEMALE; FEMUR NECK; FOLLOW UP; FRACTURE; HIP; HUMAN; LONGITUDINAL STUDY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE;

EID: 84866069886     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.427     Document Type: Erratum

References (38)

1. IMS Health Top Therapeutic Classes by Prescriptions 2011. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Static File/Top-Line-Data/2010-Top-Therapeutic-Classes-by-RX.pdf. Accessed 21 June 2011.
2. Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroentero logical Association Institute technical review on the management of gastroesophageal refux disease. Gastroenterology 2008;135:1392-413, 1413. e1391-1395.
3. Yeomans ND, Tulassay Z, Juhasz L et al. A comparisonofomeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-as-sociated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998;338:719-26.
4. Hawkey CJ, Karrasch JA, Szczepanski L et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338:727-34.
5. Laheij RJ, Sturkenboom MC, Hassing RJ et al. Riskofcommunity-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955-60.
6. Juurlink DN, Gomes T, Ko DT et al. A population-based studyofthe drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-8.
7. Dial S, Delaney JA, Barkun AN et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium dificile-associated disease. JAMA 2005;294:2989-95.
8. Yu EW, Blackwell T, Ensrud KE et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008;83:251-9.
9. Targownik LE. Another bad break for proton-pump inhibitors? Nat Rev Rheumatol 2009;5:478-80.
10. Roux C, Briot K, Gossec L et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 2009; 84: 13-9.
11. Yang YX, Lewis JD, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53.
12. Corley DA, Kubo A, Zhao W et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010; 139: 93-101.
13. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, hista-mine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006; 79: 76-83.
14. Pouwels S, Lalmohamed A, Souverein P et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 2011;22:903-10.
15. Khalili H, Huang ES, Jacobson BC et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 2012;344:e372.
16. Laine L. Proton pump inhibitors and bone fractures? Am J Gastroenterol 2009;104 (2 Suppl): S21-6.
17. Moayyedi P. Hip fracture and proton pump inhibitor therapy: position statement. Can J Gastroenterol 2008; 22: 855-8.
18. Possible fracture risk with high dose, long-term use of proton pump inhibitors. 2010. http://www.fda.gov/newsevents/newsroom/pressannouncements/ ucm213377.htm. Accessed 3 June 2011.
19. Targownik LE, Lix LM, Leung S et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010;138:896-904.
20. Gray SL, La Croix AZ, Larson J et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 2010;170: 765-71.
21. Kreiger N, Tenenhouse A, Joseph L et al. The Canadian Multicentre Osteoporosis Study (Ca Mos): background, rationale, methods. Can J Aging 1999;18:376-87.
22. Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efcacy of alendronate. Arch Intern Med 2011;171:998-1004.
23. Teramura-Gronblad M, Hosia-Randell H, Muurinen S et al. Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents. Scand J Prim Health Care 2010;28:154-9.
24. Woods NF, La Croix AZ, Gray SL et al. Frailty: emergence and consequenc-es in women aged 65 and older in the Women's Health Initiative Observational Study. J Am Geriatr Soc 2005;53:1321-30.
25. Targownik LE, Lix LM, Metge CJ et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179:319-26.
26. O'Connell MB, Madden DM, Murray AM et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005;118:778-81.
27. Recker RR. Calcium absorption and achlorhydria. N Engl J Med 1985;313:70-3.
28. Wright MJ, Proctor DD, Insogna KL et al. Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev 2008;66:103-8.
29. Gagnemo-Persson R, Hakanson R, Sundler F et al. Growth of the parathyroid glands in omeprazole-treated chickens. Scand J Gastroenterol 1994;29: 493-7.
30. Grimelius L, Johansson H, Lundqvist G et al. The parathyroid glands in experimentally induced hypergastrinemia in the rat. Scand J Gastroenterol 1977;12:739-44.
31. Cui GL, Syversen U, Zhao CM et al. Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats. Scand J Gastroenterol 2001;36:1011-5.
32. Mizunashi K, Furukawa Y, Katano K et al. Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993;53:21-5.
33. Bo-Linn GW, Davis GR, Buddrus DJ et al. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest 1984;73:640-7.
34. Graziani G, Badalamenti S, Como G et al. Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. Nephron 2002; 91: 474-9.
35. Wright MJ, Sullivan RR, Gafney-Stomberg E et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res 2010; 25: 2205-11.
36. Schinke T, Schilling AF, Baranowsky A et al. Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med 2009;15:674-81.
37. Tuukkanen J, Vaananen HK. Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int 1986;38:123-5.
38. Kocher MS, Kasser JR. Osteopetrosis. Am J Orthop 2003;32:222-8.